191 related articles for article (PubMed ID: 26555014)
1. Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.
Tai CJ; Li CL; Tai CJ; Wang CK; Lin LT
J Vis Exp; 2015 Oct; (105):e53124. PubMed ID: 26555014
[TBL] [Abstract][Full Text] [Related]
2. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
3. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry.
Hsu WC; Chang SP; Lin LC; Li CL; Richardson CD; Lin CC; Lin LT
Antiviral Res; 2015 Jun; 118():139-47. PubMed ID: 25865056
[TBL] [Abstract][Full Text] [Related]
4. Strategies for antiviral screening targeting early steps of virus infection.
Peng T
Virol Sin; 2010 Aug; 25(4):281-93. PubMed ID: 20960301
[TBL] [Abstract][Full Text] [Related]
5. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
6. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
[TBL] [Abstract][Full Text] [Related]
7. Screening of small-molecule compounds as inhibitors of HCV entry.
Yang JP; Zhou D; Wong-Staal F
Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
[TBL] [Abstract][Full Text] [Related]
9. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
Calland N; Sahuc ME; Belouzard S; Pène V; Bonnafous P; Mesalam AA; Deloison G; Descamps V; Sahpaz S; Wychowski C; Lambert O; Brodin P; Duverlie G; Meuleman P; Rosenberg AR; Dubuisson J; Rouillé Y; Séron K
J Virol; 2015 Oct; 89(19):10053-63. PubMed ID: 26202241
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
11. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
[TBL] [Abstract][Full Text] [Related]
12. Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.
Hwang JY; Kim HY; Park DS; Choi J; Baek SM; Kim K; Kim S; Seong S; Choi I; Lee HG; Windisch MP; Lee J
Bioorg Med Chem Lett; 2013 Dec; 23(23):6467-73. PubMed ID: 24125883
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
14. Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions.
Kim HY; Kong S; Oh S; Yang J; Jo E; Ko Y; Kim SH; Hwang JY; Song R; Windisch MP
Antiviral Res; 2016 May; 129():39-46. PubMed ID: 26850830
[TBL] [Abstract][Full Text] [Related]
15. Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus.
Chamoun-Emanuelli AM; Pécheur EI; Chen Z
Antiviral Res; 2014 Sep; 109():141-8. PubMed ID: 25019406
[TBL] [Abstract][Full Text] [Related]
16. Entry inhibitors and future treatment of hepatitis C.
Fofana I; Jilg N; Chung RT; Baumert TF
Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
[TBL] [Abstract][Full Text] [Related]
17. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
18. Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16.
Wang JY; Lin CJ; Liu CH; Lin LT
J Vis Exp; 2019 Jul; (149):. PubMed ID: 31355786
[TBL] [Abstract][Full Text] [Related]
19. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
[TBL] [Abstract][Full Text] [Related]
20. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092
[No Abstract] [Full Text] [Related]
[Next] [New Search]
